Workflow
Theratechnologies(THTX)
icon
Search documents
Theratechnologies(THTX) - 2021 Q3 - Earnings Call Transcript
2021-10-13 15:24
Financial Data and Key Metrics Changes - Theratechnologies reported a 27% growth in overall results for Q3 2021 compared to the same period in 2020, with sales of $17.9 million for the quarter and $51.1 million for the first nine months of the year [38][39] - EGRIFTA sales increased by 64% year-over-year to $11.2 million in Q3 2021, reflecting a recovery from the pandemic's impact [39] - Trogarzo sales decreased by 7.8% year-over-year to $6.6 million, affected by COVID-19 and new competition in the market [40] - R&D expenses rose to $8.3 million in Q3 2021 from $4.2 million in the same quarter last year, driven by the advancement of oncology programs [42] - The net loss for Q3 2021 was $9.5 million, or $0.10 per share, compared to a net loss of $6.8 million, or $0.09 per share, in Q3 2020 [47] Business Line Data and Key Metrics Changes - EGRIFTA sales showed a significant increase due to a return to face-to-face meetings and enhanced digital marketing efforts, leading to a 40% increase in new prescribers [28] - Trogarzo faced challenges due to COVID-19 and competition, but new prescription numbers have shown improvement since the start of Q4 2021 [40][41] - The company is advancing its SORT 1+ technology in oncology, with a focus on TH1902 for treating sortilin-positive cancers, and plans to initiate a Phase 1 Part B trial in early 2022 [15][19] Market Data and Key Metrics Changes - The company is making progress in securing pricing and reimbursement agreements in several countries outside the U.S., including Italy, where Trogarzo is expected to become commercially available by the end of FY 2021 [30][31] - The pandemic has accelerated the healthcare industry's shift towards digital health, impacting engagement between healthcare providers and patients [25][26] Company Strategy and Development Direction - Theratechnologies aims to unlock the value in its commercial business through product lifecycle management and innovation while advancing its investigational pipeline [9][10] - The company is exploring partnerships in Greater China for TH1902 to expedite development for patients with sortilin-expressing cancers [19][20] - The strategic focus includes evaluating different dosing schedules and potential partnerships to enhance the therapeutic window and efficacy of its oncology treatments [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery of the commercial landscape and the potential for growth based on Q3 results [37] - The company remains committed to advancing its Phase 3 program in NASH and is actively seeking partnerships to support this initiative [23][24] - Management highlighted the importance of the ongoing Phase 1 trial for TH1902, with encouraging early indications of safety and efficacy [36][92] Other Important Information - The company appointed Dr. Mace Rothenberg as a scientific advisor for its SORT 1+ technology platform, bringing extensive experience from his previous role at Pfizer [17][18] - Theratechnologies is also planning to initiate a post-authorization study named the Trogarzo PROMISE trial to evaluate long-term efficacy and safety [34] Q&A Session Summary Question: Can you elaborate on the pricing of Trogarzo in the EU and the competition from Rukobia? - Management confirmed achieving a solid price in Italy, which will serve as an anchor point for negotiations in Europe, and acknowledged Rukobia's significant presence in the U.S. market [52][54][56] Question: What are the plans for the Canadian market and business development updates? - EGRIFTA is approved in Canada, but the focus will shift to the F8 formulation next year, with ongoing discussions for partnerships and interest in the oncology platform from Chinese companies [58][60] Question: Regarding R&D expenses, should the current level be expected to continue? - Management indicated that the current R&D expenses are sustainable, with ongoing projects in oncology expected to ramp up [66] Question: Can you provide insights on the PROMISE studies and their purpose? - The PROMISE trial is a post-marketing obligation in Europe, aimed at providing hands-on experience for KOLs and enhancing interactions with physicians [68][69] Question: What is the breakdown of the decline in Trogarzo sales? - The decline was attributed to multiple factors, including COVID-19 impacting patient visits and competition from Rukobia, which offers a pill form [73][75] Question: What is the status of reimbursement plans in Europe for Trogarzo? - Management reported progress in negotiations, particularly in Italy, with expectations for reimbursement by the end of the year and further launches in early to mid-2022 [78][80] Question: Is the grade 4 SAE observed in the TH1902 trial indicative of the maximum tolerated dose? - Management clarified that more data is needed to determine the maximum tolerated dose, and the trial is on track with encouraging results so far [80][82]
Theratechnologies(THTX) - 2021 Q2 - Earnings Call Transcript
2021-07-15 17:19
Theratechnologies Inc. (NASDAQ:THTX) Q2 2021 Earnings Conference Call July 15, 2021 8:30 AM ET Company Participants Denis Boucher - VP, Communications and Corporate Affairs Paul Levesque - President and CEO Philippe Dubuc - SVP and CFO Christian Marsolais - SVP and CMO Conference Call Participants André Uddin - Mackie Research Capital Edward Nash - Canaccord Genuity Endri Leno - National Bank Operator Good morning ladies and gentlemen and thank you for standing by. Welcome to the Theratechnologies Conferenc ...
Theratechnologies (THTX) Investor Presentation - Slideshow
2021-04-23 22:48
| --- | --- | --- | --- | |-------------------------|-------|-------|---------------------------------------| | | | | | | | | | | | | | | | | NASDAQ: THTX TSX: TH | | | CORPORATE PRESENTATION April 16, 2021 | Forward-Looking Information | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | The following presentation contains statements that are considered forward-looking informat ...
Theratechnologies(THTX) - 2021 Q1 - Earnings Call Transcript
2021-04-14 15:42
Theratechnologies Inc. (NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications and Corporate Affairs Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Theratechnologies Conference Call. At this time, all participants are in a listen-only mode. [Operator Instruction ...
Theratechnologies (THTX) Investor Presentation - Slideshow
2021-03-10 18:14
| --- | --- | --- | --- | |-------------------------|-------|-------|--------------------------------------| | | | | | | | | | | | | | | | | NASDAQ: THTX TSX: TH | | | CORPORATE PRESENTATION March 5, 2021 | Forward-Looking Information | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | The following presentation contains statements that are considered forward-looking informatio ...
Theratechnologies(THTX) - 2020 Q4 - Earnings Call Transcript
2021-02-28 04:34
Theratechnologies Inc. (NASDAQ:THTX) Q1 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants Denis Boucher - VP of Communications & Corporate Affairs Paul Levesque - President, CEO & Director Philippe Dubuc - Senior VP & CFO Christian Marsolais - Senior VP & Chief Medical Officer Conference Call Participants Andre Uddin - Mackie Research Capital Edward Nash - Canaccord Genuity Corp Endri Leno - National Bank Financial, Inc Operator Ladies and gentlemen, thank you for standing by. ...
Theratechnologies(THTX) - 2020 Q2 - Earnings Call Transcript
2020-07-15 16:21
Theratechnologies Inc. (NASDAQ:THTX) Q2 2020 Earnings Conference Call July 15, 2020 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications and Corporate Affairs Paul Lévesque - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer Jovan Antunovic - Chief Commercial Officer Conference Call Participants Leonid Timashev - RBC Capital Markets Endri Leno - National Bank Operator Good morning, ladies and gentlemen, and thank you for standi ...
Theratechnologies(THTX) - 2020 Q1 - Earnings Call Transcript
2020-04-14 18:38
Theratechnologies Inc. (NASDAQ:THTX) Q1 2020 Earnings Conference Call April 14, 2020 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications & Corporate Affairs Paul Lévesque - President & Chief Executive Officer Philippe Dubuc - Senior Vice President & Chief Financial Officer Jovan Antunovic - Chief Commercial Officer Christian Marsolais - Senior Vice President & Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets André Uddin - Mackie Research Capi ...
Theratechnologies(THTX) - 2019 Q4 - Earnings Call Transcript
2020-02-25 19:21
Theratechnologies Inc. (NASDAQ:THTX) Q4 2019 Earnings Conference Call February 25, 2020 8:30 AM ET Company Participants Denis Boucher - VP, C&CA Luc Tanguay - CEO, President Philippe Dubuc - CFO, SVP Jovan Antunovic - CCO Conference Call Participants Edward Nash - Canaccord Genuity Andre Uddin - Mackie Research Capital Corp Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Theratechnologies Conference Call. At this time, all participants are in a listen-only mode. Fo ...
Theratechnologies(THTX) - 2019 Q3 - Earnings Call Transcript
2019-10-08 17:44
Theratechnologies Inc. (THERF) Q3 2019 Results Earnings Conference Call October 8, 2019 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications and Corporate Affairs Luc Tanguay - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer Jovan Antunovic - Senior Vice President and Chief Commercial Officer Christian Marsolais - Senior Vice President and Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets ...